|  1)                                           Compared to OXA-48, it shows impaired acti  | 
|  2)                                           Compared to animal models, in vitro models  | 
|  3)                                           Compared to control, polypharmacy reduced   | 
|  4)                                           Compared to controls, patients with idiopa  | 
|  5)                                           Compared to conventional methods, this lab  | 
|  6)                                           Compared to free Ceph, LNFs were significa  | 
|  7)                                           Compared to healthy individuals (8 studies  | 
|  8)                                           Compared to low doses of gamma irradiation  | 
|  9)                                           Compared to mice without the ΔKPQ-Scn5a m  | 
|  10)                                           Compared to normative data during the equi  | 
|  11)                                           Compared to other allied health profession  | 
|  12)                                           Compared to other asthma comorbidities, ob  | 
|  13)                                           Compared to other major ethnic groups, Whi  | 
|  14)                                           Compared to recreational cannabis users, m  | 
|  15)                                           Compared to reduced-intensity conditioning  | 
|  16)                                           Compared to the AMI model group, STVNa adm  | 
|  17)                                           Compared to the amount of research that ha  | 
|  18)                                           Compared to the phase 3 platform trials th  | 
|  19)                                           Compared to the pre-lockdown period, the c  | 
|  20)                                           Compared to their normal weight peers, ove  | 
|  21) evels of insulin, C-peptide, and HOMA2-IR compared to 0-5% weight loss.  | 
|  22) for those with a provider recommendation, compared to 0.5% to 44.7% for those withou  | 
|  23) 1-SD strain treated with 6.4 mg L-1 nZVIs compared to 3.2 mg L-1 nZVIs.  | 
|  24) n Israel discussed Power/Class Asymmetry, compared to 37 per cent in Italy.  | 
|  25)  (prevalence ranging from 12.8 to 13.4%), compared to 4.4-5.1% in the two U.S.  | 
|  26) d denervation-induced muscle atrophy when compared to 8-month-old mice.  | 
|  27)          NPs showed efficient activity as compared to ACE, and finally, the bacteria  | 
|  28) ) respectively, suppressing the growth as compared to ACE.  | 
|  29) solated from epsin-deficient animals when compared to ApoE-/- controls.  | 
|  30) al brain tissue and cultured neurons when compared to ApoE3+/+ counterparts.  | 
|  31) gnitive impairment (MCI) or early AD when compared to ApoE4-/- subjects.  | 
|  32) (A) Root growth of SB is slightly more as compared to B-385 in control conditions in  | 
|  33) showed hypersensitivity to 200 μM Cr(VI) compared to B-385 in terms of primary root  | 
|    |